Vertex secures FDA clearance for infants’ cystic fibrosis therapy
Pharmaceutical Technology
MAY 4, 2023
The approval allows KALYDECO to be used in infants who have at least one mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to the therapy, on the basis of clinical and/or in vitro assay results.
Let's personalize your content